Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Daily Lactobacillus Probiotic versus Placebo in COVID-19-Exposed Household Contacts (PROTECT-EHC): A Randomized Clinical Trial

Paul E. Wischmeyer, Helen Tang, Yi Ren, Lauren Bohannon, Zeni E. Ramirez, Tessa M. Andermann, Julia A. Messina, Julia A. Sung, David Jensen, Sin-Ho Jung, Alexandra Artica, Anne Britt, Amy Bush, Ernaya Johnson, Meagan V. Lew, Hilary M. Miller, Claudia E. Pamanes, Alessandro Racioppi, Aaron T. Zhao, View ORCID ProfileNeeraj K. Surana, Anthony D. Sung
doi: https://doi.org/10.1101/2022.01.04.21268275
Paul E. Wischmeyer
1Department of Anesthesiology, Duke University School of Medicine Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Tang
2Duke University School of Medicine Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Ren
3Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Duke Cancer Institute Biostatistics Shared Resources, Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Bohannon
4Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zeni E. Ramirez
5Department of Molecular Genetics and Microbiology, Duke University, Division of Infectious Diseases, Department of Pediatrics, Duke University, Medical Center Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tessa M. Andermann
6Division of Infectious Diseases, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia A. Messina
7Division of Infectious Diseases, Department of Medicine, Duke University Medical Center Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia A. Sung
6Division of Infectious Diseases, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Jensen
1Department of Anesthesiology, Duke University School of Medicine Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sin-Ho Jung
10Department of Biostatistics and Bioinformatics, Duke University School of Medicine Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandra Artica
4Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Britt
4Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Bush
4Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ernaya Johnson
4Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meagan V. Lew
4Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hilary M. Miller
4Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia E. Pamanes
17Department of Neurosurgery, Duke University Medical Center Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandro Racioppi
4Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aaron T. Zhao
19Duke University Trinity College of Arts & Sciences Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neeraj K. Surana
20Department of Molecular Genetics and Microbiology, Duke University, Department of Immunology, Duke University Medical Center, Division of Infectious Diseases, Department of Pediatrics, Duke University Medical Center Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Neeraj K. Surana
Anthony D. Sung
4Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center Durham, North Carolina, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: anthony.sung@duke.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

STRUCTURED ABSTRACT

Importance The COVID-19 pandemic continues to pose unprecedented challenges to worldwide health. While vaccines are effective, supplemental strategies to mitigate the spread and severity of COVID-19 are urgently needed. Emerging evidence suggests susceptibility to infections, including respiratory tract infections, may be reduced by probiotic interventions; therefore, probiotics may be a low-risk, widely implementable modality to mitigate risk of COVID-19 disease, particularly in areas with low vaccine availability and/or uptake.

Objective To determine whether daily probiotic Lactobacillus rhamnosus GG (LGG) is effective in preventing development of symptoms of illness within 28 days of COVID-19 exposure.

Design This randomized, double-blind, placebo-controlled trial across the United States (PROTECT-EHC) enrolled in 2020-2021. Participants were followed for 60 days.

Setting Describe the study setting to assist readers to determine the applicability of the report to other circumstances, for example, multicenter, population-based, primary care or referral center(s), etc.

Participants Participants included individuals ≥ 1 year of age with a household contact with a recent (≤ 7 days) diagnosis of COVID-19. 182 participants were enrolled and randomized during the study period.

Intervention Participants were randomized to receive daily oral LGG or microcrystalline cellulose placebo for 28 days.

Main Outcomes and Measures The primary outcome was development of symptoms within 28 days of exposure to a COVID-19-infected household contact. Stool was collected to evaluate for changes in microbiome structure.

Results 182 participants were enrolled and randomized during the study period. Intention-to-treat analysis showed that participants randomized to LGG were less likely to develop symptoms versus those randomized to placebo (26.4% vs. 42.9%, p=0.02). Further, LGG was associated with a statistically significant reduction in COVID-19 diagnosis (log rank p=0.049) via time-to-event analysis. Overall incidence of COVID-19 diagnosis did not significantly differ between LGG and placebo groups (8.8% vs. 15.4%, p=0.17). LGG was well-tolerated with no increased side effects versus placebo. Placebo recipients were more likely to stop the study product, temporarily or permanently, due to symptoms attributed to the study product (5.5% vs. 0%, p = 0.02).

Conclusions and Relevance Our study suggests that LGG is well-tolerated and is associated with prolonged time to development of COVID-19 infection, reduced incidence of symptoms, and changes to gut microbiome structure when used as post-exposure prophylaxis within 7 days after exposure. This preliminary work may inform the approach to prevention of COVID-19, particularly in underdeveloped nations where Lactobacillus probiotics have already been utilized to reduce non-COVID sepsis and infectious-morbidity. This study was limited by its remote format, which necessitated a primary endpoint of self-reported symptoms rather than laboratory-confirmed infection; further laboratory-based studies are needed to further define the efficacy of LGG in preventing COVID-19 infection, especially in larger populations and including comparison of pre-exposure vs. post-exposure prophylaxis.

Trial registration ClinicalTrials.gov, NCT04399252, https://clinicaltrials.gov/ct2/show/NCT04399252

Question Is daily probiotic Lactobacillus rhamnosus GG (LGG) effective in preventing development of symptoms of illness compatible with COVID-19 within 28 days of COVID-19 exposure compared to placebo?

Findings In this randomized clinical trial that included 182 participants, the proportion who developed symptoms was 26.4% with LGG versus 42.9% with placebo, a significant difference.

Meaning LGG probiotic may protect against the development of symptoms when used as post-exposure prophylaxis within 7 days after COVID-19 exposure.

Competing Interest Statement

P.E.W. has received unrestricted gift funding from DSM/iHealth and has a research grant from Abbott.

Clinical Trial

NCT04399252

Clinical Protocols

https://bmjopen.bmj.com/content/11/5/e047069

Funding Statement

This work was supported by a grant from the Duke Microbiome Center to A.D.S. and P.E.W. and private philanthropic donations to A.D.S. DSM/iHealth donated the LGG and placebo for the trial but had no role in its design, conduct, analysis, or writing.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of Duke University gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Microbiome sequencing data will be made available in the Sequence Read Archive (upon manuscript acceptance). We do not plan to share individual participant data.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 05, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Daily Lactobacillus Probiotic versus Placebo in COVID-19-Exposed Household Contacts (PROTECT-EHC): A Randomized Clinical Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Daily Lactobacillus Probiotic versus Placebo in COVID-19-Exposed Household Contacts (PROTECT-EHC): A Randomized Clinical Trial
Paul E. Wischmeyer, Helen Tang, Yi Ren, Lauren Bohannon, Zeni E. Ramirez, Tessa M. Andermann, Julia A. Messina, Julia A. Sung, David Jensen, Sin-Ho Jung, Alexandra Artica, Anne Britt, Amy Bush, Ernaya Johnson, Meagan V. Lew, Hilary M. Miller, Claudia E. Pamanes, Alessandro Racioppi, Aaron T. Zhao, Neeraj K. Surana, Anthony D. Sung
medRxiv 2022.01.04.21268275; doi: https://doi.org/10.1101/2022.01.04.21268275
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Daily Lactobacillus Probiotic versus Placebo in COVID-19-Exposed Household Contacts (PROTECT-EHC): A Randomized Clinical Trial
Paul E. Wischmeyer, Helen Tang, Yi Ren, Lauren Bohannon, Zeni E. Ramirez, Tessa M. Andermann, Julia A. Messina, Julia A. Sung, David Jensen, Sin-Ho Jung, Alexandra Artica, Anne Britt, Amy Bush, Ernaya Johnson, Meagan V. Lew, Hilary M. Miller, Claudia E. Pamanes, Alessandro Racioppi, Aaron T. Zhao, Neeraj K. Surana, Anthony D. Sung
medRxiv 2022.01.04.21268275; doi: https://doi.org/10.1101/2022.01.04.21268275

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1097)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9773)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2313)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1562)
  • Health Policy (736)
  • Health Systems and Quality Improvement (604)
  • Hematology (238)
  • HIV/AIDS (504)
  • Infectious Diseases (except HIV/AIDS) (11650)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (238)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2144)
  • Nursing (134)
  • Nutrition (337)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1180)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2182)
  • Public and Global Health (4663)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)